This Glasgow Biotech Just Raised $46M to Tackle a Rare Kidney Disease

Jan de Vries · 2026-08-07

There's something quietly exciting happening in the world of rare disease treatment, and it's coming out of Glasgow. Mironid, a biopharmaceutical company focused on degenerative and genetic kidney conditions, just closed a hefty Series B round. We're talking about $46 million (€39.9 million) in fresh capital, and it's all going toward pushing its lead drug candidate through clinical trials. That candidate targets Autosomal Dominant Polycystic Kidney Disease, or ADPKD, a condition that's far more common than most people realize. In fact, it affects over 12 million people worldwide. To put that in perspective, that's roughly the population of New York City and Los Angeles combined. And here's the sobering part: about half of those patients will develop kidney failure by age 60. ### Who's backing this bet? The round was led by the Scottish National Investment Bank, which is a pretty strong vote of confidence. But they're not alone. The syndicate includes some heavyweight names like Roche Venture Fund, Sofinnova Partners, and BioGeneration Ventures, along with Epidarex Capital and the University of Strathclyde. When you see that mix of corporate venture arms and specialist healthcare investors, it signals real conviction in the science. Neil Wilkie, Mironid's CEO, didn't mince words about what this means. He framed the funding as validation of the company's approach, and honestly, it's hard to argue with that logic. High-calibre investors don't throw money at risky science without seeing something promising. ### The science behind the headlines So what makes Mironid different? The company spun out of the University of Strathclyde and Heriot-Watt University back in 2015, building on over three decades of research into PDE biology by Professor Miles Houslay. That's a long runway of academic groundwork. Their lead candidate is what they call a LoAc small molecule. Without getting too deep into the weeds, it works by targeting cyclic AMP, or cAMP, a cellular signal that's active throughout the entire disease process. Think of it like this: ADPKD causes fluid-filled cysts to grow uncontrollably in the kidneys. The company's approach aims to stop new cysts from forming while also halting the growth of existing ones. Preclinical data has reportedly shown significant efficacy, including reductions in cyst number and kidney volume, with a favorable safety profile. That's the kind of result that gets investors excited, but it's still early days. Clinical development is where many promising drugs go to die, so the real test is ahead. ### Why this matters beyond one company This isn't just a win for Mironid. It's a signal that Scotland's biotech scene is maturing. Paul Callaghan from the Scottish National Investment Bank called it an example of translating world-class research into clinical progress. That's not just PR speak; it reflects a broader trend of university spinouts attracting serious capital. - The company's total funding since inception now stands at roughly $47 million (€40.8 million) - The pipeline extends beyond ADPKD to target PDE4 enzymes, which are implicated in inflammatory diseases and cancer - The team is led by industry veterans, not just academics ### The road ahead There's a long way to go before this becomes a commercial therapy. Clinical trials are expensive, time-consuming, and brutally unforgiving. But the potential payoff is enormous, both for patients and for investors who got in early. For the millions of people living with ADPKD, the current treatment landscape is limited. A more durable option with fewer side effects could genuinely change lives. And that's the real story here. It's not just about a funding round; it's about the possibility of transforming how we treat a devastating disease. Will Mironid succeed? Nobody knows yet. But with this kind of backing and a clear scientific rationale, they've certainly given themselves a fighting chance. And in the world of rare disease research, that's more than most companies ever get.